

Medical Management

Off-Label Prescribing of GLP-1 Agents

Louisiana Blue covers Food and Drug Administration (FDA)-approved GLP-1 receptor agonists and GIP/GLP-1 receptor agonists only for the treatment of Type 2 diabetes mellitus. These include but are not limited to: Trulicity®, Ozempic®, Rybelsus®, Mounjaro®, liraglutide (Victoza® and generics) and exenatide. All other uses of these medications are considered investigational per the FDA.

We will continue to review claims for compliant prescribing and billing. If future issues are noted, this could affect your network status and/or have other legal implications.

Our medical policy governing the use of these drugs can be found in our Medical Policy index, available on our Provider page, www.lablue.com/providers. Click "Medical Management," then "Medical Policies."